What Pulse Biosciences Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 4 | 6 |
| Sells | 0 | 7 |
| Total trades | 4 | 20 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 4,095 | 804,328 |
| Disposed | 0 | 125,000 |
| Net activity | +4,095 | +679,328 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Teplitsky Liane Rae | Chief Operating Officer | Sep 01 | Open-market buy · P | +1,001 | $49.95 | +$50K | 4,095 |
| Teplitsky Liane Rae | Chief Operating Officer | Aug 31 | Open-market buy · P | +1,024 | $48.80 | +$50K | 3,094 |
| Teplitsky Liane Rae | Chief Operating Officer | Aug 28 | Open-market buy · P | +1,034 | $48.35 | +$50K | 2,070 |
| Teplitsky Liane Rae | Chief Operating Officer | Aug 26 | Open-market buy · P | +1,036 | $48.24 | +$50K | 1,036 |
| Laviolette Paul A | Chief Executive Officer | May 11 | Open-market buy · P | +15,000 | $19.69 | +$295K | 15,846 |
| Duggan Robert W | Director | May 11 | Open-market buy · P | +660,233 | $19.69 | +$13M | 48,370,047 |
| Danahy Kevin Patrick | Chief Commercial Officer | Feb 18 | Open-market sale · S | −5,000 | $23.64 | −$118K | 43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer | Feb 18 | Exercise / conversion · M | +5,000 | $1.53 | +$7.65K | 48,298 |
| Danahy Kevin Patrick | Chief Commercial Officer | Feb 17 | Open-market sale · S | −20,000 | $23.63 | −$473K | 43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer | Feb 17 | Exercise / conversion · M | +20,000 | $1.53 | +$30.6K | 63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer | Feb 13 | Open-market sale · S | −20,000 | $23.53 | −$471K | 43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer | Feb 13 | Exercise / conversion · M | +20,000 | $1.53 | +$30.6K | 63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer | Feb 12 | Open-market sale · S | −20,000 | $23.37 | −$467K | 43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer | Feb 12 | Exercise / conversion · M | +20,000 | $1.53 | +$30.6K | 63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer | Feb 11 | Open-market sale · S | −20,000 | $25.20 | −$504K | 43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer | Feb 11 | Exercise / conversion · M | +20,000 | $1.53 | +$30.6K | 63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer | Feb 10 | Open-market sale · S | −20,000 | $23.52 | −$470K | 43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer | Feb 10 | Exercise / conversion · M | +20,000 | $1.53 | +$30.6K | 63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer | Feb 09 | Open-market sale · S | −20,000 | $21.45 | −$429K | 43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer | Feb 09 | Exercise / conversion · M | +20,000 | $1.53 | +$30.6K | 63,298 |
Loading...
